Retained Earnings (Accumulated Deficit) in USD of RVL Pharmaceuticals plc from Q4 2018 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
RVL Pharmaceuticals plc quarterly Retained Earnings (Accumulated Deficit) history and change rate from Q4 2018 to Q2 2023.
  • RVL Pharmaceuticals plc Retained Earnings (Accumulated Deficit) for the quarter ending 30 Jun 2023 was -$605M, a 12.7% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

RVL Pharmaceuticals plc Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2023 -$605M -$68.3M -12.7% 30 Jun 2023 10-Q 14 Aug 2023
Q1 2023 -$581M -$56.5M -10.8% 31 Mar 2023 10-Q 11 May 2023
Q4 2022 -$569M -$51.7M -9.99% 31 Dec 2022 10-Q 14 Aug 2023
Q3 2022 -$551M -$53.1M -10.7% 30 Sep 2022 10-Q 10 Nov 2022
Q2 2022 -$536M -$56.5M -11.8% 30 Jun 2022 10-Q 11 Aug 2022
Q1 2022 -$524M -$62.1M -13.4% 31 Mar 2022 10-Q 12 May 2022
Q4 2021 -$518M -$64.9M -14.3% 31 Dec 2021 10-K 20 Mar 2023
Q3 2021 -$498M -$100M -25.2% 30 Sep 2021 10-Q 15 Nov 2021
Q2 2021 -$480M -$90.8M -23.3% 30 Jun 2021 10-Q 16 Aug 2021
Q1 2021 -$462M -$86.1M -22.9% 31 Mar 2021 10-Q 13 May 2021
Q4 2020 -$453M -$79.6M -21.3% 31 Dec 2020 10-K 30 Mar 2022
Q3 2020 -$398M -$51.4M -14.8% 30 Sep 2020 10-Q 10 Nov 2020
Q2 2020 -$389M -$156M -66.8% 30 Jun 2020 10-Q 11 Aug 2020
Q1 2020 -$376M -$268M -246% 31 Mar 2020 10-Q 12 May 2020
Q4 2019 -$373M -$271M -265% 31 Dec 2019 8-K 08 Sep 2021
Q3 2019 -$346M 30 Sep 2019 10-Q 14 Nov 2019
Q2 2019 -$233M 30 Jun 2019 10-Q 08 Aug 2019
Q1 2019 -$109M 31 Mar 2019 10-Q 09 May 2019
Q4 2018 -$102M 31 Dec 2018 10-K 19 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.